Enveric Biosciences Return on Equity

Enveric Biosciences (ENVB) currently reports a ROE of -126.72%. That is below the Technology sector average of 54.72%. Use the charts on this page to explore Enveric Biosciences's ROE history and peer comparisons.

Enveric Biosciences's ROE of -126.72% is lower than the Technology sector average of 54.72%. That is roughly 331.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Enveric Biosciences's current -126.72% should be judged against Technology norms (sector average: 54.72%) and against ENVB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -126.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 54.72%. From there, open related valuation or income-statement pages for Enveric Biosciences, and consider following ENVB for alerts when major investors trade the stock.

Enveric Biosciences is classified in the Technology sector. On ROE, it currently shows -126.72% versus a sector average near 54.72%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing ENVB with unrelated industries.